Cohance Lifesciences Limited

7%

ales Pg. 2 Why Suven is uniquely positioned to win ⚫ Global Pharma CDMO is ~$135B+ market (with ~7% CAGR) of which small molecule outsourced APIs & Intermediates is ~$70B. Majority of new molecule a

13%

along with improving capabilities of Indian players o India outsourcing market likely to grow at ~13% vs. global market of 7% from EU (inflation and regulatory) and China (supply o While traditionall

20%

d) multiple engines of growth; positioning it well to win in this market o Consistent growth: 16-20% revenue CAGR across multiple 5-year periods in history o Best-in-class financial metrics: 70%+ mate

70%

h: 16-20% revenue CAGR across multiple 5-year periods in history o Best-in-class financial metrics: 70%+ material margins; 40%+ EBITDA margin; 50%+ RoCE and ~60% operating cash flow conversion o Customer

40%

across multiple 5-year periods in history o Best-in-class financial metrics: 70%+ material margins; 40%+ EBITDA margin; 50%+ RoCE and ~60% operating cash flow conversion o Customer relationships: Revenue

50%

ar periods in history o Best-in-class financial metrics: 70%+ material margins; 40%+ EBITDA margin; 50%+ RoCE and ~60% operating cash flow conversion o Customer relationships: Revenues largely from marqu

60%

istory o Best-in-class financial metrics: 70%+ material margins; 40%+ EBITDA margin; 50%+ RoCE and ~60% operating cash flow conversion o Customer relationships: Revenues largely from marquee large cap ph

35%

5 0 0 2 7 0 0 2 9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small M

29%

0 2 7 0 0 2 9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small Molecu

65%

7 0 0 2 9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small Molecules

71%

0 2 9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small Molecules Biolo

21%

9 0 0 2 1 1 0 2 3 1 0 2 5 1 0 2 7 1 0 2 9 1 0 2 1 2 0 2 … D T Y 3 2 0 2 35% 29% 65% 71% 21% 79% 37% 28% 41% 63% 72% 59% 2017 2018 2019 2020 2021 2022 Small Molecules Biologics